Freeze-dried plasma is blood plasma that has been stripped of its water through a process called lyophilization, leaving behind a lightweight, shelf-stable powder that can be stored at room temperature and reconstituted with sterile water in minutes. Its appeal is straightforward: conventional frozen plasma needs a freezer and roughly half an hour to thaw before it can be transfused, which makes it impractical in helicopters, on battlefields, or in rural ambulances far from a blood bank. Freeze-dried plasma sidesteps that problem entirely, and its development tells a story that runs from World War II field hospitals to modern combat medics and civilian trauma systems.
A World War II Idea, Revived
The concept of drying plasma is older than most people realize. During World War II, Canadian researchers led by Charles H. Best adapted a plasma isolation and drying technique originally developed by Charles R. Drew to supply dried serum for British casualties on the front lines. The program eventually ended because blood-borne disease transmission could not be reliably prevented with the testing technology of the era.1British Journal of Haematology. Past meets present: Reviving 80‐year‐old Canadian dried serum from World War II and its significance in advancing modern freeze‐dried plasma for prehospital management of haemorrhage For decades after that, fresh frozen plasma became the standard, and the dried form was largely shelved. Modern advances in pathogen testing and pathogen-reduction technologies eventually made it safe to revisit the idea, and several countries have since developed their own freeze-dried plasma products.
What Happens to Plasma When You Remove the Water
The central question with any dried blood product is whether the active ingredients survive the process. Plasma’s value in trauma comes from its clotting factors, the proteins that help stop bleeding. Lyophilization involves freezing the plasma and then dropping the pressure so the ice sublimates directly into vapor, leaving a dry cake of proteins and salts. The worry is that this freeze-dry cycle damages the delicate clotting proteins.
Laboratory studies consistently show that most clotting factors hold up well. One study comparing freeze-dried plasma to fresh frozen plasma found no differences in coagulation profiles, confirming that the lyophilization process did not decrease clotting factor activity.2Journal of Trauma and Acute Care Surgery. Development and Testing of Freeze-Dried Plasma for the Treatment of Trauma-Associated Coagulopathy A more recent characterization study found that clot formation properties and coagulation parameters were largely comparable to fresh plasma, with some minor variations observed in a couple of specialized pathways.3Transfusion. Freeze‐dried plasma: Hemostasis and biophysical analyses for damage control resuscitation Work on a U.S. military freeze-dried product showed that factor activity levels stayed within a 20% difference of the input plasma, a threshold the FDA has generally accepted for demonstrating comparability to the existing standard.4Military Medicine. Retention of Coagulation Factors and Storage of Freeze-Dried Plasma
Not all clotting factors are equally hardy, though. Factors V and VIII are the most vulnerable. In one study, factor V activity in unprotected control plasma dropped to about 44% and factor VIII to about 58% by the end of storage. Adding glycine as a stabilizer during the freeze-drying process improved those numbers to roughly 60% and 74%, respectively. Protein C, by contrast, showed no degradation at all.5PubMed. Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers The upshot is that freeze-dried plasma is not a perfect clone of what went into the freeze-dryer, but it retains enough functional clotting activity to be clinically useful. Getting the formulation right, choosing the right stabilizers and pH adjusters, has been a major focus of development work.
Why Getting Plasma to Patients Faster Matters
Severe bleeding after trauma triggers a cascade of problems beyond just losing blood volume. The body can develop what clinicians call trauma-induced coagulopathy, a state where the blood’s own clotting ability breaks down. This happens early, sometimes within minutes of a major injury, and it makes the bleeding harder to control. Research on balanced resuscitation, giving plasma alongside red blood cells rather than just saline, suggests that early plasma administration can reduce markers of damage to the blood vessel lining, and that this reduction is associated with improved survival.6Journal of Thrombosis and Haemostasis. Mechanisms and management of the coagulopathy of trauma and sepsis: trauma-induced coagulopathy, sepsis-induced coagulopathy, and disseminated intravascular coagulation
The practical problem is timing. Fresh frozen plasma sits in hospital blood banks at minus 18 degrees Celsius or colder and takes 20 to 30 minutes to thaw. For a patient bleeding on a roadside or a battlefield, that delay can be fatal. Freeze-dried plasma, by contrast, can be carried in a medic’s pack and mixed with water for injection at the point of care in just a few minutes.7PubMed Central. Dried Plasma for Major Trauma: Past, Present, and Future This is the core argument for the product: it is not necessarily better plasma, but it is plasma that can reach the patient when plasma is needed most.
The French Military Experience
France has been the global leader in freeze-dried plasma adoption, with a product known as FLYP (French Lyophilized Plasma) in routine use by the French Armed Forces Health Service for decades. Hemovigilance data collected since 1994 have shown no reported infections related to FLYP use, and clinical monitoring data from overseas military operations have confirmed its safety and efficacy.8Transfusion. The evolving role of lyophilized plasma in remote damage control resuscitation in the French Armed Forces Health Service
One of the most striking findings from French military hospitals involves speed. In a study comparing FLYP with conventional fresh frozen plasma in severe trauma patients, the time from arrival to first plasma transfusion was about 15 minutes in the FLYP group versus 95 minutes with FFP. Because plasma was available so much faster, patients in the FLYP group reached a balanced transfusion ratio sooner. The FLYP group also had far fewer cases of massive transfusion: about 7% compared to 45% in the FFP group.9Journal of Trauma and Acute Care Surgery. Use of French lyophilized plasma transfusion in severe trauma patients is associated with an early plasma transfusion and early transfusion ratio improvement Those numbers reflect a military teaching hospital where FLYP was already stocked and ready, but they illustrate what happens when you eliminate the thaw-time bottleneck.
The Israeli Defense Force has also adopted freeze-dried plasma at the point of injury. A feasibility study of that program found that medics could safely and practically administer it in the field, supporting its use in prehospital settings.10Journal of Trauma and Acute Care Surgery. Prehospital administration of freeze-dried plasma, is it the solution for trauma casualties?
Head-to-Head Against Fresh Frozen Plasma
A randomized trial comparing FLYP to fresh frozen plasma in civilian trauma patients with coagulopathy found that FLYP produced a higher fibrinogen concentration 45 minutes after treatment, with a greater improvement in clotting time and in the levels of factors V and II. Those differences persisted at six hours. Patients who received FLYP also needed less supplemental fibrinogen concentrate.11PubMed. French lyophilized plasma versus fresh frozen plasma for the initial management of trauma-induced coagulopathy: a randomized open-label trial On the surface, this looks like freeze-dried plasma may actually outperform its frozen counterpart, at least by laboratory measures. One likely explanation is that FLYP is available immediately, so clotting factor replacement begins earlier, whereas FFP patients wait through the thaw period and start falling further behind.
Lab studies reinforce the functional similarity. A bench comparison found that freeze-dried plasma was similar to pooled liquid plasma in its ability to support clot formation and resist fibrinolysis, the process that breaks clots down. About 97% of proteins were conserved through the freeze-drying process.12PubMed Central. Freeze-dried plasma enhances clot formation and inhibits fibrinolysis in the presence of tissue plasminogen activator similar to pooled liquid plasma In other words, the dried product does essentially the same job once it is reconstituted.
Where the Clinical Evidence Gets Complicated
Despite encouraging lab findings and operational experience, the randomized clinical trial evidence for freeze-dried plasma improving hard outcomes like survival has been frustratingly thin. A systematic review and meta-analysis pooling data from two studies, totaling 119 patients, found no significant difference in mortality between freeze-dried plasma and comparator treatments. The pooled odds ratio for death was 0.66, meaning a trend toward benefit but with wide confidence intervals that crossed 1.0, so the result could easily have been due to chance.13PubMed Central. Freeze-dried plasma for major trauma – Systematic review and meta-analysis
The British RePHILL trial, which tested freeze-dried plasma plus packed red blood cells against saline in prehospital trauma care, found no effect on mortality.14PubMed. Prehospital Freeze-Dried Plasma in Trauma: A Critical Review A separate randomized trial testing prehospital lyophilized plasma for trauma-induced coagulopathy found that it was not associated with reduced clotting times and yielded no convincing evidence of effectiveness for that specific indication.15JAMA Network Open. Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock: A Randomized Clinical Trial
These results deserve context. The trials were small, and trauma research is notoriously hard to do well. Patients arrive in wildly different conditions, consent is complicated, and blinding is nearly impossible. It is also worth noting that the question these trials answer is not “Is freeze-dried plasma a good product?” but rather “Does adding freeze-dried plasma in the prehospital phase, on top of everything else, move the needle on mortality?” Those are different questions. The product can be functionally equivalent to FFP in the lab while still not showing a survival benefit in a trial, especially if the comparator group gets adequate treatment at the hospital. What the French operational data suggest is that the real advantage may be the speed of delivery rather than the properties of the product itself.
Shelf Life, Storage, and What Happens After Expiration
One of freeze-dried plasma’s biggest selling points is its logistics profile. It can be stored at room temperature for up to two years, is lightweight, and takes up far less space than frozen plasma.16Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. The role of freeze-dried plasma in a world of whole blood: a Canadian prehospital and transport perspective For military supply chains, disaster-response stockpiles, and rural ambulance services, these advantages are enormous. You do not need a freezer, a generator to keep the freezer running, or a cold chain during transport.
An interesting wrinkle is what happens when freeze-dried plasma sits around longer than its labeled shelf life, or when it endures rough storage conditions. A study of units stored in uncontrolled field conditions found that the safety and efficacy of the product were only slightly affected even past the expiration date, suggesting that the labeled shelf life may actually be conservative.17PubMed. Post-expiry stability of freeze-dried plasma under field conditions – Can shelf life be extended? That matters for stockpiling: if you are keeping freeze-dried plasma in a disaster preparedness cache, knowing it may still be usable past its label date could reduce waste significantly.
Safety and Pathogen Reduction
The blood-borne disease risk that killed the World War II dried-serum program has been addressed by modern pathogen reduction technologies. These treatments target a broad range of viruses and bacteria, going well beyond the standard four pathogens that routine donor screening tests for.18Extreme Medicine. Freeze-dried plasma for emergency transfusion care in extreme conditions Because freeze-dried plasma is typically made from pooled donations that have been pathogen-reduced before lyophilization, the resulting product carries a lower infectious risk than a single-donor unit of fresh frozen plasma that has undergone only standard screening.
On the side-effect front, a porcine combat casualty study testing several freeze-dried plasma products reported no adverse effects associated with transfusion of any of the products throughout the experiments.19Transfusion. Efficacy and safety of novel freeze‐dried plasma products in a porcine combat casualty model Combined with the long French hemovigilance record showing no reported infections from FLYP use, the safety profile looks reassuring. That said, freeze-dried plasma still carries the same transfusion reaction risks as any plasma product, including allergic reactions and, in rare cases, transfusion-related acute lung injury. It is not risk-free, just safer from an infectious standpoint than earlier generations.
Freeze-Dried vs. Spray-Dried and Other Emerging Alternatives
Lyophilization is not the only way to dry plasma. Spray-drying, which atomizes plasma into a heated chamber where water evaporates almost instantly, is an alternative approach that can be faster and cheaper to scale up. Both freeze-dried and spray-dried plasma can be mass-produced, stockpiled at room temperature, and reconstituted quickly.20PubMed Central. Dried Plasma for Major Trauma: Past, Present, and Future The trade-off is that spray-drying exposes proteins to heat, which can damage some clotting factors differently than freezing does. Research is ongoing to determine which method produces a better end product, and different countries have pursued different approaches.
Beyond dried plasma altogether, some researchers are working on synthetic blood substitutes, including platelet substitutes and hybrid nanotechnologies that aim to provide hemostatic support without relying on donated blood at all.21Annals of Blood. New developments and future trends of artificial blood These are still in early stages and unlikely to replace plasma products anytime soon, but they represent the longer-term horizon. For now, freeze-dried plasma occupies a practical middle ground: a real product, already fielded by multiple militaries, that solves an immediate logistical problem even as the science continues to refine it.
Where Freeze-Dried Plasma Fits in Civilian Medicine
Most of the operational experience with freeze-dried plasma comes from military settings, but the civilian applications are obvious. Rural emergency services, where a trauma patient might face a 45-minute helicopter ride before reaching a hospital with a blood bank, are perhaps the most natural fit. Disaster-response stockpiles are another. After earthquakes, hurricanes, or mass-casualty events, cold-chain infrastructure is often the first thing to fail, making frozen blood products unavailable exactly when they are needed most.
The regulatory landscape varies by country. France has used FLYP for decades. Germany and several other European countries have their own approved products. In the United States, freeze-dried plasma has been available under emergency military protocols but has not yet received full FDA licensure for routine civilian use as of recent years, though development programs are moving it closer. Canada has been evaluating how freeze-dried plasma fits into its prehospital and transport medicine framework, particularly given the country’s vast geography and the challenges of providing blood products in remote and northern communities.22Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. The role of freeze-dried plasma in a world of whole blood: a Canadian prehospital and transport perspective
One complication for civilian adoption is the growing interest in prehospital whole blood, which provides red cells, plasma, and platelets in a single product and avoids the need to mix components. Where whole blood is available and the cold chain can support it, some trauma systems may prefer it over a reconstituted plasma product. Freeze-dried plasma is most compelling precisely where whole blood is hardest to supply: remote locations, prolonged transport times, and austere environments where refrigeration cannot be guaranteed.
Common Misconceptions Worth Clearing Up
A few misunderstandings tend to circulate around this topic. One is that freeze-dried plasma is somehow synthetic or artificial. It is not. It starts as regular human donated plasma, pooled from multiple donors, and then has its water removed. The proteins, clotting factors, and other components are all derived from real blood donations.
Another misconception is that freeze-dried plasma is universally better than fresh frozen plasma. The evidence does not support that. In controlled lab settings, the two are functionally comparable, with freeze-dried plasma showing slight losses in a couple of the more fragile clotting factors. Where freeze-dried plasma excels is in logistics: availability, portability, speed of preparation. If you are in a hospital with a well-stocked blood bank and a plasma thawer, fresh frozen plasma works perfectly well. Freeze-dried plasma solves a different problem.
A third is the assumption that because individual randomized trials have not shown mortality benefits, the product does not work. The trials conducted so far have been small, and they were testing the prehospital addition of freeze-dried plasma in systems that already provide reasonably good hospital-based care. Showing a mortality benefit on top of an already decent standard of care requires very large trials, which are expensive and logistically daunting in trauma. The absence of a statistically significant mortality reduction in small trials is not the same as evidence that the product is ineffective, and the coagulation data and operational experience from France and Israel tell a more encouraging story than the headline trial results alone.